Brazil: Positive Advances In Brazil

Last Updated: 6 November 2013
Article by Luiz Leonardos and Ricardo Dutra Nunes

Luiz Leonardos and Ricardo Dutra Nunes review the legal framework for patents in Brazil and recent developments in the system.

The Brazilian patent system is one of the oldest: it was created more than 200 years ago, in 1809, by royal decree. Since then, the country experienced many changes in this area, with several developments in our legal framework having occurred in the recent past.

Our federal constitution was enacted in 1988, establishing that "the law will guarantee a temporary privilege of use to authors of industrial inventions, as well as the protection of industrial creations (...), in view of the social interest and the technological and economic development of the country". Brazil is also a member of most of the international treaties governing patent protection. In fact, the current patent statute (Law # 9.279/96) was enacted in 1996, just after Brazil became a member of the World Trade Organization in 1995. The current statute was important to adapt the local rules to the minimum standards established by the WTO-TRIPS Agreement. For that reason, the Brazilian patent statute is reasonably similar to the ones in force in the US, Europe, and other WTO-members, although its implementation by the Brazilian executive and judiciary powers can be quite different.

In addition to the Federal Constitution, international treaties, and the patent statute, patents are also governed by regulation and guidelines enacted by the INPI (National Institute of Industrial Property), analogous to the US Patent and Trademark Office and the European Patent Office, in charge of examining patent applications.

Since Brazil joined the WTO, the INPI must issue patents in all fields of technology, including the pharmaceutical area, which was not allowed in light of the previous legal framework. The INPI must issue a patent as far as the application discloses a technical solution to a technical problem, complies with the technical requirements – such as novelty, inventive step and industrial applicability – and is not prohibited by the statute.

The patent system

The statute establishes some matters are not considered as inventions, and cannot be subject to patent protection, such as discoveries, scientific theories, mathematical methods, abstract concepts, business methods, software per se, methods of treatment, methods of diagnostic, surgical techniques, and natural living beings and biological material found in nature or isolated thereof, for example. Some other matters are considered "not patentable", such as anything contrary to public safety, order or health, some products and processes resulting from the transformation of the atomic nucleus, and living beings, except for transgenic microorganisms that are not mere discoveries.

Brazil has a first-to-file system, with a priority scheme that assimilates the Paris Convention and a 12-month grace period for disclosures made by the inventor or third parties (including the INPI) based on information received directly or indirectly from the inventor or as a result of his acts. Where a patent is granted, it gives the patent owner the right to prevent third parties from manufacturing, using, offering for sale, selling or importing the invention without his consent, for a period of 20 years as from the filing date. The extension of the protection is conferred by the claims, which are construed based on the specification and drawings.

The statute also provides for a few exceptions to patent rights, such as the experimental use exception and the Bolar exception, the later related to acts performed for the sole purpose of producing test results and data in order to obtain marketing registration for the patented product after the patent expires, which is especially relevant in case of pharmaceutical patents. Although extremely rare, a patent might be subject to compulsory licensing in some very specific circumstances.

Patent lawsuits in Brazil

In Brazil, patent infringement lawsuits are filed by the patent owner before state trial courts. Preliminary ex parte injunctions are available, allowing the trial court judge to immediately order the defendant to stop using or selling the patented invention, to conduct searches and seizures, or to order a recall of the infringing products, for instance. Depending on the amount of evidence the plaintiff presents with the complaint, to show the plaintiff will most likely prevail on the merits and that they may suffer irreparable harm – or a harm that is hard to repair – in cases where the injunction request is not granted, it is possible to obtain a preliminary ex parte injunction order in less than 24 hours after filing the case, as we have managed to obtain in the past on behalf of our clients. Declaratory non-infringement lawsuits are also available and must be filed before state trial courts as well.

Lawsuits challenging an act performed by the INPI, such as a decision issuing or rejecting a patent application, on the other hand, are typically filed before a federal district court in the city of Rio de Janeiro, where we have our main offices. Because the city has specialized district and appellate courts to deal with intellectual property matters, each case is randomly assigned to one of its four specialized IP district courts, and each appeal is assigned to one of its two specialized appellate divisions. We have learned from our experience that most of the few district court and appellate judges in charge of those cases in Rio de Janeiro are in general reluctant to overrule a decision issued by the INPI, and are frequently considered anti-patent judges. In light of that, our law firm developed an innovative – and successful – forum-shopping strategy to be able to file those lawsuits in Brasilia, our federal capital, where one of its more than fifty non-biased federal district court judges will deal with the case.

Data package exclusivity

In recent years, our law firm has also pioneered filing lawsuits to enforce our clients data package exclusivity rights, provided for both by the TRIPS Agreement and the local provisions regarding unfair competition. Such rights are especially relevant to research-based pharmaceutical companies, who must submit a huge amount of information to the ANVISA (the Brazilian Food & Drug Agency) to demonstrate their innovative products are safe and effective. In some situations, enforcing the mentioned data package exclusivity rights is the only way to avoid the free riding performed by generic industries seeking to rely on the innovator company's data package to obtain marketing approval to their generic versions, instead of performing their own clinical trials.

Another recent major change that affects pharmaceutical companies in Brazil is the new patent prosecution procedure for the analysis of pharmaceutical patent applications. Since the last decade, pharmaceutical patents cannot be issued without the ANVISA's prior consent. Until now, the INPI would examine a pharmaceutical application and forward it to the ANVISA only in cases where the examination performed by the INPI determined that the patentability requirements were met. There is no legal provision, however, expressly regulating the basis for the ANVISA to grant or reject its prior consent with regard to a patent application. Until recently, the ANVISA was insisting on reexamining the patentability requirements already examined by the INPI, denying prior approval in cases where it disagrees with the technical opinions issued by the INPI.

Two years ago, after our law firm filed many lawsuits on behalf of our clients to challenge such illegal understanding, the Attorney General's Office issued an opinion clarifying that the patentability analysis should only be performed by the INPI, and that the ANVISA should grant or deny prior approval exclusively based on issues related to public health. To avoid further controversy, the government decided to change the procedure with regard to pharmaceutical applications. Now, the application is filed with the INPI, which immediately forwards it to the ANVISA if the application is related to a pharmaceutical product or process. Subsequently, the ANVISA will examine the application in light of public health issues, granting or rejecting its prior approval. The application will then be returned to the INPI, which will shelve the application if the prior approval is denied by the ANVISA, or perform the examination of the patentability requirements if the prior approval is granted by the ANVISA, eventually issuing or denying the patent.

INPI activities

In recent years, the INPI has also taken a few important measures that affect the patent system. First of all, the INPI is doing a decent job at dealing with the huge backlog, even though its more than 400 patent examiners still take an average of 5.4 years to examine a patent application after an examination request is filed. The INPI's objective is to hire more patent examiners to decrease the average examination time to four years. This is crucial, especially because in some fields of technology, such as chemical, biotech and electric, an applicant might still have to wait more than ten years to have their patent application duly examined. Part of the success in dealing with the backlog was due to a modernization of the INPI's workflow and IT structure. Now a portion of its office actions are available online, and the INPI has just launched a system that will soon make it possible to file a patent application online.

In an attempt to contribute to the development of innovative green technologies, the INPI developed in April a fast-track procedure to examine some patent applications related to alternative energies and energy conservation, transportation, waste management and agriculture. This expedite procedure is already available and can dramatically reduce the time taken by the INPI to examine the application. Also, the INPI created a new optional procedure for applications originally filed in Brazil, allowing the applicant to request the INPI to perform a preliminary analysis and issue a preliminary opinion with regard to the patentability requirements. This preliminary opinion might be relevant to give the applicant more information about their chances of ultimately obtaining a patent.

In addition to that, the INPI drafted new general guidelines for the examination of patent applications, and society is currently reviewing this first draft to suggest insertions and adjustments. The INPI also drafted new guidelines for the examination of polymorphs, providing applicants with more legal certainty in this sophisticated field that was deemed to be a grey area before the specific guidelines were published, since some specialists were trying to sustain that polymorphic inventions were not patentable.

In spite of the many challenges faced by national and foreign companies with regard to the ever evolving Brazilian patent system, the country has witnessed some positive advances in recent years, as the executive, legislative and judiciary powers understand the importance of having a vigorous and practical structure that stimulates the technological and economic development of the country.

Originally published in The Patent Lawyer.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.